Search
Naldemedine
go.drugbank.com/drugs/DB11691ApprovedInvestigationalNaldemedine is an opioid receptor antagonist [FDA Label]. … Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opioid-induced Constipation.
Categories: Peripheral Opioid Receptor AntagonistsWarfarin
go.drugbank.com/drugs/DB00682ApprovedInvestigationalWarfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion … Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration.
Eletriptan
go.drugbank.com/drugs/DB00216ApprovedInvestigationalEletriptan is a second generation triptan drug developed by Pfizer Inc for the treatment of migraine headaches.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Receptor AgonistsProducts: RELERTHexocyclium
go.drugbank.com/drugs/DB06787ApprovedHexocyclium is a muscarinic acetylcholine receptor antagonist which was presumably used in the treatment of gastric ulcer or diarrhea. … Proton pump inhibitors like [DB00338] and opiate anti-diarrheal agents like [DB00836] have largely replaced the use of anti-muscarinics in the treatment of gastric ulcers and diarrhea due to their more
Lumiracoxib
go.drugbank.com/drugs/DB01283ApprovedWithdrawnOn August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver … New Zealand and Canada have also followed suit in recalling the drug.
Molybdenum
go.drugbank.com/drugs/DB11137ApprovedInvestigationalWhen complexed with Technetium Tc 99m, molybdenum is used as a radiopharmaceutical agent in diagonistic procedures.
Mixtures: Venexa FE, Ribotin-EDelamanid
go.drugbank.com/drugs/DB11637ApprovedInvestigationalIt is used in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis (TB) in a combination regimen. … Spontaneous resistance to delamanid was observed during treatment, where mutation in one of the 5 F420 coenzymes responsible for bioactivation of delamanid contributes to this effect [L1407].
Zidovudine
go.drugbank.com/drugs/DB00495ApprovedInvestigationalA dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. … This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains.
Mixtures: LAMIVUDINA E ZIDOVUDINA MYLAN, LAMIVUDINA E ZIDOVUDINA MYLANCategories: Antivirals used in combination for the treatment of HIV infectionsGinkgo biloba
go.drugbank.com/drugs/DB01381ApprovedInvestigationalNutraceutical[A232389] Most of the studies that investigate the effect of _ginkgo biloba_ use the standardized extract of _Ginkgo biloba_ (EGb) 761 (EGb761), which was developed by a German pharmaceutical company in … [A232379] _Ginkgo folium_, the leaf extract of _Ginkgo biloba_, is considered an anti-dementia drug by the World Health Organization.[A232389]
Products: EXTRACTO DE GINKO BILOBA AL 24 % EQUIVALENTE A 9.6 MG DE GLICOSIDOS FLAVONOIDES.Lipegfilgrastim
go.drugbank.com/drugs/DB13200ApprovedIt aims to reduce the duration of neutropenia and the incidence of febrile neutropenia. … Granulocyte colony-stimulating factors (G-CSFs) were introduced in the 1980's to the clinical setting to stimulate neutrophil proliferation and differentiation, thereby reducing the duration and severity